Synovus Financial’s Heron Therapeutics HRTX Stock Holding History

Synovus Financial’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-31,847	Closed	-$70.1K	–	924
2025 Q1	$70.1K	Hold	31,847	–	–	﹤0.01%	885
2024 Q4	$48.7K	Hold	31,847	–	–	﹤0.01%	867
2024 Q3	$63.4K	Hold	31,847	–	–	﹤0.01%	905
2024 Q2	$111K	Buy	+31,847	New	+$97.8K	﹤0.01%	828
2020 Q3	–	Sell	-130	Closed	-$2K	–	1009
2020 Q2	$2K	Sell	130 -470	-78%	-$7.72K	﹤0.01%	1428
2020 Q1	$8K	Buy	600 +470	+362%	+$8.84K	﹤0.01%	1634
2019 Q4	$3K	Hold	130	–	–	﹤0.01%	1375
2019 Q3	$2K	Hold	130	–	–	﹤0.01%	1388
2019 Q2	$2K	Hold	130	–	–	﹤0.01%	1319
2019 Q1	$3K	Hold	130	–	–	﹤0.01%	1300
2018 Q4	$3K	Hold	130	–	–	﹤0.01%	1269
2018 Q3	$4K	Buy	+130	New	+$4.84K	﹤0.01%	1260

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Synovus Financial's HRTX Position: Q2 2025 in Review

Synovus Financial sold out of Heron Therapeutics (HRTX) in Q2 2025, closing a stake of 31,847 shares — an estimated $70.1K sold.

Synovus Financial first reported a position in HRTX in Q3 2018 and held it in 12 quarters. The position peaked at $111K in Q2 2024. 171 funds tracked by Wall St. Rank hold HRTX as of Q2 2025.

Synovus Financial reported no remaining Heron Therapeutics position as of Q2 2025 after selling out during the quarter.
Synovus Financial sold 31,847 Heron Therapeutics shares in Q2 2025, an estimated $70.1K.
Synovus Financial first reported a position in Heron Therapeutics in Q3 2018 and held it in 12 quarters.
Synovus Financial's Heron Therapeutics position peaked at $111K in Q2 2024.
171 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2025.

Based on Synovus Financial's 13F filing for Q2 2025, filed 14 Aug 2025.